AfghanistanTuberculosis profile
Population  2014 32 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 14 (10–18) 44 (32–57)
Mortality (HIV+TB only) 0.087 (0.072–0.1) 0.28 (0.23–0.33)
Prevalence  (includes HIV+TB) 110 (56–180) 340 (178–555)
Incidence  (includes HIV+TB) 60 (53–67) 189 (167–212)
Incidence (HIV+TB only) 0.32 (0.25–0.4) 1 (0.8–1.3)
         
Case detection, all forms (%) 53 (47–60)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.2 (2.3–4.1) 17 (11–23)
MDR-TB cases among notified pulmonary
TB cases
750 (540–960) 360 (240–490)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 14 737   1 209
Pulmonary, clinically diagnosed 8 573    
Extrapulmonary 7 227    
       
Total new and relapse 31 746    
Previously treated, excluding relapses 966    
Total cases notified 32 712    
Among 30 537 new cases:
4 454 (15%) cases aged under 15 years; male:female ratio: 0.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 (<1%) 184 (8%) 186
Laboratory-confirmed RR-/MDR-TB cases     88
Patients started on MDR-TB treatment ***     88
TB/HIV 2014 Number (%)
TB patients with known HIV status 10 443 (32)
HIV-positive TB patients 4 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 142  
HIV-positive people provided with IPT 7  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 30 507
Previously treated cases, excluding relapse, registered in 2013 (74) 1 115
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 38
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 6%
% Funded internationally 67%
% Unfunded 27%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-08 Data: www.who.int/tb/data